Amyloidosis

Annals of Clinical Biochemistry

Volumn 49, Issue 3, 2012, Pages 229-241

  Pinney, Jennifer H ^a   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; FIBRINOGEN; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PREALBUMIN;

ALPHA HELIX; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BETA HELIX; BETA SHEET; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CARDIOVASCULAR MAGNETIC RESONANCE; CELL PROLIFERATION; CLINICAL FEATURE; DIALYSIS; ECHOCARDIOGRAPHY; GENETIC VARIABILITY; HEART FAILURE; HEPATOMEGALY; HEREDITARY ATAXIA; HUMAN; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FAILURE; LASER MICROSCOPY; MASS SPECTROMETRY; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SCINTIGRAPHY; SPLENOMEGALY; SURVIVAL RATE; SURVIVAL TIME;

AMYLOID; AMYLOIDOSIS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PLAQUE, AMYLOID; PROTEIN PRECURSORS; QUALITY OF LIFE; RNA, SMALL INTERFERING;

EID: 84861493080     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011225     Document Type: Review

References (125)

1. Pepys MB. Amyloidosis. In: Frank MM, Austen KF, Claman HN, Unanue ER, eds. Samter's Immunologic Diseases. 5th edn. Boston: Little, Brown and Company, 1994:637-655
2. Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 2001;356:203-10
3. Westermark P, Araki S, Benson MD, et al. Nomenclature of amyloid fibril proteins. Amyloid: Int J Exp Clin Invest 1999;6:63-6
4. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507-11
5. Uversky VN, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 2004;1698:131-53
6. Nielsen L, Khurana R, Coats A, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001;40:6036-46
7. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001;276:27207-13
8. Sunde M, Serpell LC, Bartlam M, et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997;273:729-39
9. Jaroniec CP, MacPhee CE, Bajaj VS, et al. High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc Natl Acad Sci USA 2004;101:711-16
10. Pepys MB, Rademacher TW, Amatayakul-Chantler S, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994;91:5602-6
11. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995;92:4299-303
12. Kisilevsky R, Fraser P. Proteoglycans and amyloid fibrillogenesis. Ciba Found Symp 1996;199:58-67
13. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10
14. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-9
15. Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010;5:2180-7
16. Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011;68:195-9
17. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-13
18. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-28
19. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93
20. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92:343-9
21. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010;122:138-44
22. Tabbibizar R, Maisel A. The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol 2002;17:340-5
23. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91
24. Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009;20:444-51
25. Granel B, Valleix S, Serratrice J, et al. Lysozyme amyloidosis: report of 4 cases and a review of the literature. Medicine (Baltimore) 2006;85: 66-73
26. Haagsma EB, Hawkins PN, Benson MD, et al. Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid 2004;11:44-4
27. Landau HJ, Comenzo RL, Zhou P, et al. AL amyloidosis in a patient with a T60A TTR mutation. XIth International Symposium on Amyloidosis. Florida: CRC Press, 2008:160-162
28. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489-91
29. Gregorini G, Izzi C, Obici L, et al. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005;16:3680-6
30. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59
31. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84
32. Pasternak S, White VA, Gascoyne RD, et al. Monoclonal origin of localised orbital amyloidosis detected by molecular analysis. Br J Ophthalmol 1996;80:1013-7
33. Westermark P, Sletten K, Pitkanen P, Natvig JB, Lindholm CE. Localized laryngeal amyloidosis: partial characterization of an amyloid fibril protein AL. Mol Immunol 1982;19:447-50
34. Lewis JE, Olsen KD, Kurtin PJ, Kyle RA. Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg 1992;106:372-7
35. Goodman HJB, Bridoux F, Lachmann HJ, et al. Localized amyloidosis: clinical features and outcome in 235 cases. Hematologica 2005;90 (Suppl. 1):203 [abstract]
36. Gandhi D, Wee R, Goyal M. CT and MR imaging of intracerebral amyloidoma: case report and review of the literature. AJNR Am J Neuroradiol 2003;24:519-22
37. Parmar H, Rath T, Castillo M, Gandhi D. Imaging of focal amyloid depositions in the head, neck, and spine: amyloidoma. AJNR Am J Neuroradiol 2010;31:1165-70
38. Pehlivanov B, Belovegdov V, Ivanov G, Ivancheva H. Primary localised amyloidosis of the vagina. Aust N Z J Obstet Gynaecol 2008;48:120-2
39. Tirzaman O, Wahner-Roedler DL, Malek RS, et al. Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000;75:1264-8
40. Shah PL, Gillmore JD, Copley SJ, et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:134-42
41. Kurrus JA, Hayes JK, Hoidal JR, Menendez MM, Elstad MR. Radiation therapy for tracheobronchial amyloidosis. Chest 1998;114:1489-92
42. Nugent AM, Elliott H, McGuigan JA, Varghese G. Pulmonary amyloidosis: treatment with laser therapy and systemic steroids. Respir Med 1996;90:433-5
43. Shikama Y, Kitazawa J, Yagihashi N, et al. Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med 2010;49:397-401
44. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood 2001;98:714-20
45. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999;104:131-7
46. Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001;97:1885-7
47. Fish R, Pinney J, Jain P, et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010;5:1977-80
48. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJ Med 1998;91:141-57
49. Levine RA. Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients. Am J Med 1962;33:349-57
50. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine 1975;54:271-99
51. Levy M, Fryd CH, Eliakim M. Intrahepatic obstructive jaundice due to amyloidosis of the liver. A case report and review of the literature. Gastroenterology 1971;61:234-8
52. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal AL amyloidosis following chemotherapy. J Clin Oncol 2011;29:674-81
53. Klein AL, Hatle LK, Burstow DJ, et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;15:99-108
54. Goodman HJ, Gillmore JD, Lachmann HJ, et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417-25
55. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378-83
56. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000;25:465-70
57. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011;86:12-18
58. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93
59. Sattianayagam PT, Gibbs SDJ, Pinney JH, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010;10:2124-31
60. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-9
61. Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-53
62. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71
63. de Beer FC, Mallya RK, Fagan EA, et al. Serum amyloid A protein (SAA) concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;ii:231-4
64. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology 1999;38:499-503
65. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1-11
66. Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006;16:294-9
67. Dember LM, Jaber BL. Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial 2006;19:105-9
68. Bernier GM, Conrad ME. Catabolism of human beta-2-microglobulin by the rat kidney. AmJ Physiol 1969;217:1359-62
69. Campistol JM, Ponz E, Munoz-Gomez J, et al. Renal transplantation for dialysis amyloidosis. Transplant Proc 1992;24:118-9
70. Westermark P, Sletten K, Johansson B, Cornwell GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843-5
71. Cornwell GG, 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75:618-23
72. Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003;10(Suppl 1):48-54
73. Kyle RA, Gertz MA, Linke RP. Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type. Am J Clin Pathol 1992;97:250-3
74. Takei Y, Hattori T, Gono T, et al. Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Amyloid 2002;9:252-5
75. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9
76. Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101:395-400
77. Nyhlin N, Anan I, el-Salhy M, Ando Y, Suhr OB. Endocrine cells in the upper gastrointestinal tract in relation to gastrointestinal dysfunction in patients with familial amyloidotic polyneuropathy. Amyloid 1999;6:192-8
78. Lobato L. Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). J Nephrol 2003;16:438-42
79. Said G. Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 2003;10(Suppl 1):7-12
80. Sousa MM, Saraiva MJ. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 2003;71:385-400
81. Benson MD, Uemichi T. Transthyretin amyloidosis. Amyloid: Int J Exp Clin Invest 1996;3:44-56
82. Reilly MM, King RH. Familial amyloid polyneuropathy. Brain Pathol 1993;3:165-76
83. Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 1995;59:45-9
84. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004;17:615-20
85. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73
86. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol 2003;17:909-27
87. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242-6
88. Holmgren G, Ericzon B-G, Groth C-G, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-6
89. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71
90. Stangou AJ, Booth DR, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998. Pearl River, New York: Parthenon Publishing, 1999:330-332
91. Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;274:702-6
92. Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1969;1:314-24
93. de la Chapelle A, Tolvanen R, Boysen G, et al. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 1992;2:157-60
94. Kazmirski SL, Isaacson RL, An C, et al. Loss of a metal-binding site in gelsolin leads to familial amyloidosis-Finnish type. Nat Struct Biol 2002;9:112-6
95. Burtnick LD, Urosev D, Irobi E, Narayan K, Robinson RC. Structure of the N-terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF. EMBO J 2004;23:2713-22
96. Chen CD, Huff ME, Matteson J, et al. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 2001;20:6277-87
97. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid: Int J Exp Clin Invest 1998;5:55-66
98. Maury CPJ, Alli K, Baumann M. Finnish hereditary amyloidosis. Amino acid sequence homology between the amyloid fibril protein and human plasma gelsoline. FEBS Lett 1990;260:85-7
99. Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogena-chain. Nat Genet 1993;3:252-5
100. Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 2010;115:2998-3007
101. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6
102. Castro G, Nihoul LP, Dengremont C, et al. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry 1997;36:2243-9
103. Eriksson M, Schonland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 2009;11:257-62
104. Obici L, Palladini G, Giorgetti S, et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004;126:1416-22
105. Caballeria J, Bruguera M, Sole M, Campistol JM, Rodes J. Hepatic familial amyloidosis caused by a new mutation in the apolipoprotein AI gene: clinical and pathological features. Am J Gastroenterol 2001;96:1872-6
106. de Sousa MM, Vital C, Ostler D, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000;156:1911-7
107. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 1999;257:584-8
108. Hamidi Asl L, Liepnieks JJ, Hamidi Asl K, et al. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol 1999;154:221-7
109. 174→Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 1999;155:695-702
110. Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71:986-92
111. Gillmore JD, Stangou AJ, Lachmann HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant 2006;6:2342-7
112. Weiss SW, Page DL. Amyloid nephropathy of Ostertag with special reference to renal glomerular giant cells. Am J Pathol 1973;72:447-55
113. Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int 2003;64:11-16
114. Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005;12:75-87
115. Pepys MB, inventor. Therapeutic agent. US Patent No. 7,045,499. 2006, granted 16 May 2006
116. Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans 2010;38:466-70
117. Johnson SM, Wiseman RL, Sekijima Y, et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 2005;38:911-21
118. Johnson SM, Connelly S, Wilson IA, Kelly JW. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem 2008;51:260-70
119. Tennent GA. Structural and Functional Aspects of the Pentraxins and SAA in the Acute Phase Response and Amyloidosis. PhD dissertation. London: University of London, 1995
120. Botto M, Hawkins PN, Bickerstaff MCM, et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997;3:855-9
121. Hind CRK, Collins PM, Caspi D, Baltz ML, Pepys MB. Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. Lancet 1984;ii:376-8
122. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9
123. Kolstoe SE, Ridha BH, Bellotti V, et al. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 2009;106:7619-23
124. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010;486:93-7
125. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-7